VIDEO: New CAR-T targets show activity
NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses research evaluating G protein–coupled receptor as a new target for therapy in relapsed refractory multiple myeloma.
Abstracts presented at the ASH Annual Meeting and Exposition showed patients responded to this chimeric antigen receptor T-cell therapy after failure of other B-cell maturation antigen (BCMA) therapies, including CAR T-cell therapy, according to Al Hadidi.
In the U.S., there are two approved BCMA therapies, ide-cel (idecabtagene vicleucel) and cilta-cel (ciltacabtagene autoleucel), but patients can relapse after using those products, Al Hadidi said.
“So, it is always important to find that there are other options for those patients," he said.
Collapse
Healio Interviews